COMPANY PROFILE

Kynexis

Explore full profile

Precision therapeutics for cognitive impairment in schizophrenia

Naarden, NetherlandsFounded 2023Biotech & Life Sciences

Valuation $250–500M Last recorded · 2026

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Kynexis

Kynexis is a clinical-stage biotechnology company developing precision therapeutics for cognitive disorders, with lead candidate KYN-5356, a selective oral KAT-II (kynurenine aminotransferase II) inhibitor licensed from Mitsubishi Tanabe Pharma for cognitive impairment associated with schizophrenia (CIAS) and potential expansion into Alzheimer’s and other cognitive diseases. Founded in 2023 and headquartered in Naarden, Netherlands, with a US subsidiary in Cambridge, Massachusetts, it builds on research by scientific co-founders Dr Robert Schwarcz and Dr Carol Tamminga and is led by CEO Kees Been. After an initial €57 million Series A in 2023 led by Forbion, Ysios Capital and Sunstone Life Science Ventures, Kynexis in August 2026 closed a €40 million Series A extension led by Novartis Venture Fund with Forbion, Ysios and Sunstone returning—bringing total Series A financing to €97 million ($110 million)—to close out Phase 2 CIAS activities and prepare registrational development. Sources: company 19 Aug 2026; Forbion / PharmaLetter Aug 2026.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2023
Headquarters: Naarden, Netherlands
Employees: 22
Open positions: None listed
Dealroom signal: 85.3/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Precision Medicine, Woman Founder, DT and LS, science-based
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Nov 2023	$63M	$251M	Ysios Capital · Sunstone Life Science Ventures · Forbion Capital Partners	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Kynexis website traffic

Latest recorded traffic for Kynexis is 2.1K monthly website visits, up 740% over the last three months. Kynexis's team grew 144.4% over the past year.

Latest monthly visits2.1K 3-month web change+740% 1-year team growth+144.4%

Monthly website visitsNov 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
THTheremiaLeverage AI for inclusive healthcare	Paris, France	Operational	28	$3.3M	$13M
MAMoonlight AIThe company uses AI and machine learning to analyze genomic data	Courroux, Switzerland	Operational
STSynamics TherapeuticsRedefining precision: innovating adaptive medicine through AI-powered solutions for intractable cancer	Copenhagen, Denmark	Operational
MDMI:RNA DiagnosticsVeterinary diagnostic testing using microRNA biomarkers and AI	Whitburn, United Kingdom	Operational
SLScienta LabAI-powered Precision Immunology	Gif-sur-Yvette, France	Operational
IBIMU BiosciencesAI-powered platform decoding the immune system	London, United Kingdom	Operational
YTYsotope TheranosticsTargeted radiopharmaceuticals for precision oncology	Madrid, Spain	Operational
SPStarget PharmaThis company is developing new targeted radiopharmaceutical technologies to treat solid tumors	Ramat Hasharon, Israel	Operational